sulfuric acid mono-(2-methoxy-phenyl ester); potassium salt | 6100-07-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机硫酸及其衍生物
• 英文名称: sulfuric acid mono-(2-methoxy-phenyl ester); potassium salt
• 英文别名: Schwefelsaeure-mono-(2-methoxy-phenylester); Kaliumsalz；Potassium guaiacolsulfate；potassium;(2-methoxyphenyl) sulfate
• CAS: 6100-07-8
• 化学式: C₇H₇O₅S*K
• 分子量: 242.294
• InChiKey: UFSSZNFDFJFJBF-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -2.46
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  84
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  potassium guaiacolate 在 氢氧化钾 、 potassium pyrosulfate 作用下， 生成 sulfuric acid mono-(2-methoxy-phenyl ester); potassium salt
  参考文献：
  名称：

  Tiemann; Koppe, Chemische Berichte, 1881, vol. 14, p. 2021

  摘要：

  DOI：

文献信息

• Pharmaceutical preparation containing copolyvidone
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US10098866B2

  公开（公告）日：2018-10-16

  A stabilized preparation which comprises: a unstable drug in a polyethylene glycol-containing preparation; and a coating agent comprising a copolyvidone instead of polyethylene glycol with which the drug is coated.

  一种稳定的制剂，包括：在聚乙二醇含制剂中的不稳定药物；以及一种包衣剂，其包衣剂包括一种共聚维酮，而不是用聚乙二醇包衣药物。
• Odorless formulation for treating mucosal discontinuities
  申请人：——

  公开号：US20040132810A1

  公开（公告）日：2004-07-08

  The present invention includes a method for making a formulation for treating mucosal discontinuities, comprising: providing phenolic compounds and treating the purified phenolic compounds with sulfuric acid to make sulfonic acids and sulfonate salts. The present invention also includes formulations prepared by the method.

  本发明涉及一种用于制备治疗黏膜不连续的配方的方法，包括：提供酚类化合物，并用硫酸处理纯化的酚类化合物以制备磺酸和磺酸盐。本发明还包括通过该方法制备的配方。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Treatment of colds and cough with a combination of a cyclooxygenase-2 selective inhibitor and a colds and cough active ingredient and compositions thereof
  申请人：Pharmacia Corporation

  公开号：US20040029864A1

  公开（公告）日：2004-02-12

  A method for the treatment, prevention and amelioration of colds and/or cough in a subject in need of such treatment, prevention and amelioration, comprises administering to the subject a cyclooxygenase-2 selective inhibitor or prodrug thereof and one or more colds and cough active ingredient. Compositions, pharmaceutical compositions and kits for practicing the method are also disclosed.

  本发明涉及一种用于治疗、预防和改善感冒和/或咳嗽的方法，包括向需要此类治疗、预防和改善的受试者施用环氧合酶-2选择性抑制剂或其前药以及一个或多个感冒和咳嗽活性成分。还公开了实施该方法的组合物、制药组合物和工具包。
• Modified release formulations containing drug-ion exchange resin complexes
  申请人：Mehta Ketan

  公开号：US20070215511A1

  公开（公告）日：2007-09-20

  A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described.

  提供一种涂层药物-离子交换树脂复合物，包括由药物与药用可接受的离子交换树脂形成的核心。该药物-离子交换树脂复合物与释放延迟剂混合。涂层是聚乙烯醇聚合物和增塑剂。描述了制备方法和含有此涂层复合物的产品。